Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
542 results about "Natural killer cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. The role NK cells play is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cells, acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect the major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the initial notion that they do not require activation to kill cells that are missing "self" markers of MHC class 1. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells.
Chimeric receptors with 4-1bb stimulatory signaling domain
InactiveUS20130266551A1Provide immunitySpecific and vigorous preferential expansionBiocideAntibody mimetics/scaffoldsChimeric antigen receptorBiological activation
The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Chimeric receptors with 4-1BB stimulatory signaling domain
InactiveUS20050113564A1Antibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsNatural Killer Cell Inhibitory ReceptorsT cell
The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. Also included is a method for obtaining an enriched population of NK cells from a mixed population of NK cells and T cells.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Chimeric NK receptor and methods for treating cancer
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Chimeric antigen receptors targeting B-cell maturation antigen
ActiveUS9765342B2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigenAntigen receptors
Owner:UNITED STATES OF AMERICA
Methods for preparation of glycosphingolipids and uses thereof
Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.
Owner:LIANG PI HUI
Smart CAR Devices and DE CAR Polypeptides for Treating Disease and Methods for Enhancing Immune Responses
ActiveUS20170157176A1Increase killIncrease the number of grainsPolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsDiseaseApoptosis
In an aspect, the present invention relates generally to the field of treating disease with CAR devices, Smart CAR devices, DE CAR devices, and / or Smart-DE CAR devices. The present invention also relates generally to the genetic modification of cytotoxic T-lymphocytes to reduce target cell killing by apoptosis and / or increase production of lytic proteins at desired times. In an aspect, the invention relates to the use of these genetically modified T-lymphocytes and / or natural killer cells with CAR devices, Smart CAR devices, DE CAR devices, and / or Smart-DE CAR devices to enhance the immune response against a disease.
Owner:CHIMERA BIOENG INC
Modified Natural Killer Cells and Uses Thereof
ActiveUS20170073638A1Polypeptide with localisation/targeting motifCell receptors/surface-antigens/surface-determinantsNatural Killer Cell Inhibitory ReceptorsNatural killer cell
The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and / or survival of NK cells.
Owner:NAT UNIV OF SINGAPORE +1
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
InactiveUS7157418B1Enhance and aid in survivalPrevent proliferationAntibacterial agentsBiocidePhagocyteDendritic cell
Conjugates containing as a ligand a chemokine receptor targeting agents, such as chemokines, and a targeted agent, such as a toxin are provided. These conjugates are used to treat inflammatory responses associated with activation, proliferation and migration of immune effector cells, including leukocyte cell types, neutrophiles, macrophages, and eosinophils. The conjugates provided herein are used to lessen or inhibit these processes to prevent or at least lessen the resulting secondary effects. In particular, the conjugates are used to target toxins to receptors on secondary tissue damage-promoting cells. The ligand moiety can be selected to deliver the cell toxin to such secondary tissue damage-promoting cells as mononuclear phagocytes, leukocytes, natural killer cells, dendritic cells, and T and B lymphocytes, thereby suppressing the proliferation, migration, or physiological activity of such cells. Among preferred conjugates are fusion proteins having a chemokine, or a biologically active fragment thereof, as the ligand moiety linked to a cell toxin via a peptide linker of from 2 to about 60 amino acid residues.
Owner:OSPREY PHARMA USA INC
Chimeric NK receptor and methods for treating cancer
The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Methods and Compositions for Natural Killer Cells
ActiveUS20150190471A1Reduce in quantityIncrease the number ofPeptide/protein ingredientsCulture processNatural killer cellWilms' tumor
The application provides new compositions and methods for stimulating the production of natural killer (NK) cells in a subject. NK cells can be selectively expanded with a combination of stimulating ligands. Methods and compositions for the administration of stimulatory ligands modified to self-insert into tumor cells, thereby stimulating an increase in the number of NK cells in proximity to a tumor, are also described.
Owner:UNIV OF CENT FLORIDA RES FOUND INC
Chimeric NK Receptor and Methods for Treating Cancer
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Methods for Enhancing Natural Killer Cell Proliferation and Activity
InactiveUS20130011376A1Function increaseHigh cytotoxic activityOrganic active ingredientsBiocideNatural killer cellCytokine
Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and / or functionality of NK cells by treating the cells with a nicotinamide or other nicotinamide moiety in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof.
Owner:GAMIDA CELL
Monomeric Bi-Specific Fusion Protein
The present invention embraces a bi-specific fusion protein composed of an effector cell-specific antibody-variable region fragment operably linked to at least a portion of a natural killer cell receptor. Methods for using the fusion protein in the treatment of cancer and pathogenic infections are also provided.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE
Method for culturing natural killer (NK) and/or natural killer T (NKT) cells
InactiveCN102676453ATo proliferateHigh purityBlood/immune system cellsPeripheral blood mononuclear cellMagnetic bead
The invention discloses a method for culturing natural killer (NK) and / or natural killer T (NKT) cells. The method comprises the following step: inoculating isolated NK and / or NKT cells into a culture system A for culture to obtain propagated NK and / or NKT cells, wherein the culture system A consists of a buffer solution containing CD3 antibody and / or Retronectin and inducing factors. Experiments prove that peripheral blood mononuclear cells (PBMC) extracted from peripheral blood are separated and enriched through magnetic beads, high-purity CD56+ cells are obtained, two proteins, namely Retronectin and CD3mAb are added into an in-vitro culture system for joint stimulation, and IL-2 and IL-5 factors are used for assisting in induction, so that a culture method capable of obtaining massive NK and NKT cells with high killing activity is established.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
ActiveUS20150152387A1Improve efficiencyImprove efficacyBiocideMammal material medical ingredientsNatural Killer Cell FunctionNatural killer cell
The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.
Owner:NKMAX CO LTD
Cytotoxic conjugates comprising a chemokine receptor targeting agent
InactiveUS7166702B1Enhance and aid in survivalPrevent proliferationPolypeptide with localisation/targeting motifChemokinesPhagocyteDendritic cell
Owner:OSPREY PHARMA USA INC
Natural killer cells with enhanced immune response
ActiveUS20130295044A1Avoiding unnecessary treatmentAvoid treatmentBiocideMammal material medical ingredientsInfected cellNatural killer cell
The invention relates to a specialized subpopulation of natural killer cells that have enhanced effector functions and the potential to kill malignant tumor cells or infected cells when the natural killer cells are exposed to an antibody bound to the tumor cells or the infected cells.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV
Development of natural killer cells and functional natural killer cell lines
The invention relates to natural killer cells and methods for the development of immortalized natural killer cells and use of the natural killer cells. A growth and culture system is described that supports increased natural killer cell development, and provides for the establishment of continuous natural killer cell lines. Additionally, the disclosed method for generating natural killer cells may be used to produce large numbers of natural killer cells for therapeutic applications and for natural killer cell research.
Owner:UNIV OF UTAH RES FOUND
Method for amplifying and activating NK (Natural Killer) cells by K562 cells
InactiveCN102586185AImprove immunityMammal material medical ingredientsBlood/immune system cellsCD137Natural killer cell
The invention belongs to the field of immunology and particularly provides a method for amplifying and activating a natural killer cell (NK) in an oriented way under the mutual effect of a K562 cell, which is transfected by transmembranes IL-21, CD14, CD19, CD86 and CD137, and a low-concentration interleukin 2. According to the invention, the method comprises the following steps: transcribing expression carriers, which are used for stably expressing CD8 alpha-interleukin 21, CD14, CD19, CD86 and CD137, by using K562 cell lines, wherein the CD8 alpha is a membrane protein expressed on a cell membrane, and the interleukin 21 is expressed on the cell membrane to become a transmembrane protein after the CD8 alpha gene is connected with the interleukin 21 gene; and then culturing the K562 cell for a section of time; and finally, obtaining a purified K562 cell by using a physical and chemical method and then culturing the NK cell. According to the invention, by using the amplified and activated NK cell, the immunity of the patient can be enhanced, the viruses and bacteria are resisted, and high efficiency is obtained. The method for amplifying and activating the natural killer cell, provided by the invention, medically has wide purposes.
Owner:杭州中赢方舟生物工程有限公司
Method for preparing NK (natural killer) cell
InactiveCN103484429AHigh purityBlood/immune system cellsPeripheral blood mononuclear cellMultiplication rate
The invention provides a method for efficiently preparing an NK cell, which can improve the multiplication rate and the purity of the NK cell through combination of stimulation effects of cell factors and feeder cells. The method is mainly characterized by comprising the steps as follows: NCR3LG1 and m IL-15 are transfected to a K562 cell simultaneously, m IL-15 can be used for adjusting activation and multiplication of the NK cell, NCR3LG1 serving as a ligand of NKp30 which is one of main activated receptors on the surface of the NK cell can effectively stimulate activation of the NK cell, and NCR3LG1 and m IL-15 have a synergistic effect; and PBMC(peripheral blood mononuclear cells) can be multiplied over 500 times in 21 cultivation days through stimulation of factors of freely added IL-2, IL-21 and the like, and a proportion of CD3-CD56+NK cell exceeds 70%; and up to now, a research report that NCR3LG1 and m IL-15 are transfected to the feeder cells simultaneously and jointly stimulate and activate the NK cell in combination of free cell factors is absent. The invention firstly provides a method for jointly cultivating and preparing the NK cell in combination of the feeder cells and the free factors.
Owner:青岛麦迪赛斯生物科技有限公司
In-vitro large-scale amplification method of natural killer cells
PendingCN106011061ASolve the problem of low efficiency of in vitro amplificationHigh purityCulture processBlood/immune system cellsPeripheral blood mononuclear cellMicrobiology
The invention discloses an in-vitro large-scale amplification method of natural killer cells. The method comprises the following steps: collecting and separating peripheral blood mononuclear cells; sorting natural killer cells; culturing the natural killer cells; and collecting the natural killer cells. The method utilizing immunomagnetic beads to sort the natural killer cells has the advantages of simplicity in establishing and operation, and high comprehensive efficiency; and the effect of the method adopting in-vitro amplification of the immunomagnetic bead shorted NK cells is 2-3 times the effect of present amplification methods, so the method disclosed in the invention has great application values in the field of in-vitro large-scale amplification.
Owner:GUANGDONG NO 2 PROVINCIAL PEOPLES HOSPITAL
Natural killer cell culture medium and natural killer cell amplification culture method
ActiveCN104593324AImprove efficiencyHigh purityBlood/immune system cellsMicrobiologyNatural killer cell
The invention relates to the cell culture technical field, and particularly relates to a natural killer cell culture medium and a natural killer cell amplification culture method. The invention provides the culture medium used for amplification culture of natural killer cells and containing a serum-free culture medium, human plasma, IL-2, IL-21, IL-15 and OKT-3. The culture medium provided by the invention is used for amplification culture of the natural killer cells, can avoid risks caused by exogenous serum, has high amplification efficiency and allows the obtained natural killer cells to have high purity. With adopting the method for amplification of the natural killer cells, amplification of the natural killer cells can be maintained at a logarithmic phase for a longer period of time. Moreover, the cultured natural killer cells have good killing activity on tumor cells.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD
Method for differentiating human pluripotent stem cells into natural killer cells and application
ActiveCN111235105ALow costAvoid expensiveCulture processDead animal preservationHematopoietic progenitor cell differentiationNatural Killer Cell Inhibitory Receptors
The invention relates to the field of stem cell biology, specifically to a method for differentiating human pluripotent stem cells into natural killer cells and an application. The invention disclosesa pluripotent stem cell-derived natural killer cell. The pluripotent stem cell-derived natural killer cell expresses CD56, Nkp30, Nkp44 and Nkp46, and also expresses markers CD16 and CD94 of a maturenatural killer cell. The invention also discloses a method for preparing the natural killer cell. The method comprises the following steps: S1, formation of an embryoid body; S2, differentiation of the embryoid body into hematopoietic progenitor cells; S3, differentiation of the hematopoietic progenitor cells into NK cells; and S4, maturation and expansion of the NK cells. With the differentiation method provided by the invention, the pluripotent stem cells can be rapidly, efficiently, simply and conveniently induced to be differentiated into the natural killer cells with low cost on the basis of a culture medium with definite components and an optimized cell factor combination.
Owner:安徽中盛溯源生物科技有限公司
Modified alpha-galactosyl ceramides for staining and stimulating natural killer t cells
InactiveUS20090047299A1Improve solubilityEasy loadingAntibacterial agentsBiocideNatural killer cellInvariant natural killer T-cell
Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.
Owner:BRIGHAM YOUNG UNIV +2
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
InactiveUS20130177574A1Market price thereof has been risingMinimizing IVIg related side effectAntipyreticAnalgesicsDiseaseAntigen
Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and / or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities. While anti-HLA-Ib mAbs can be used to restore anti-tumor activities of CD8+ T cells and Natural killer cells by passive therapy in cancer patients, methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.
Owner:RAVINDRANATH MEPUR DR
Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
ActiveUS20060023559A1Microbiological testing/measurementBiological material analysisEffector cellT lymphocyte
The present invention includes a method of measuring cytolytic activity including providing a device capable of monitoring cell-substrate impedance operably connected to an impedance analyzer, adding target cells to at least one well of the device, adding effector cells to the at least one well, monitoring impedance of the at least one well and optionally determining a cell index from the impedance, wherein monitoring impedance includes measuring impedance during at least one time point before and at least one time point after adding effector cells, and determining viability of said target cells after adding effector cells by comparing the impedance or optionally the cell index at the at least one time point after adding effector cells to the impedance or optionally the cell index at the at least one time point before adding effector cells
Owner:AGILENT TECH INC
In-vitro culture method of NK (natural killer) cells
InactiveCN103627672AEnhance killing activityPromote growthBlood/immune system cellsNatural Killer Cell Inhibitory ReceptorsBottle
The invention discloses an in-vitro culture method of NK (natural killer) cells and belongs to culture of human cells. The in-vitro culture method disclosed by the invention comprises the following steps: merging herceptin diluted by PBS (phosphate buffered saline) and human immunoglobulin diluted by the PBS, then uniformly and fully spreading at the bottom of a culture bottle and standing overnight; additionally taking peripheral blood, performing density gradient centrifugation, sucking a single nuclear cell, adding into a serum-free culture medium, and adjusting the concentration of the cells to 1.0*10<6> / ml-3.0*10<6> / ml; and then adding cell factors IL-2 and IL-15, adding into the culture bottle coated by the herceptin and culturing in an incubator. Therefore, on the basis of ensuring the amplification multiple of various cell subgroups, the growth and the proliferation of the NK cells are promoted, the killing activity of lymphocytes is enhanced, the serum-free culture medium can replace a serum-containing complete culture medium, the number of obtained culture products is equivalent to the activity of the cells, the in-vitro large-scale culture of the NK cells is realized, the in-vitro culture method is used for clinical biological treatment of the NK cells, and the safety in clinical application can be increased by using the in-vitro culture method.
Owner:TIANJIN MEDICAL UNIV CANCER HOSPITAL
Artificial antigen presenting cell and application thereof in NK (natural killer) cell amplification
InactiveCN102559600AHigh purityStrong cytotoxicityBlood/immune system cellsRecombinant DNA-technologyNatural Killer Cell Inhibitory Receptors4-1BB ligand
The invention provides an in vitro amplification method for efficient and highly cytotoxic natural killer (NK) cells. Novel artificial antigen presenting cells 4-1BBL-mIL-21-aAPC, such as 4-1BBL-mIL-21-K562 cells and the like, are constructed through stably expressing 4-1BB ligands (4-1BBL) and membrane immobilized interleukin 21 (mIL-21) on the surfaces of cell membranes, and by using the novel artificial antigen presenting cells as feeder cells for amplification, the NK cells are directly amplified from peripheral blood lymphocytes. Flow cytometry, cytotoxicity test and the like suggest that the amplified cells NK have high purity and strong cytotoxicity and have obvious killing effect on tumor cells.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Culturing method of NK (natural killer) cell
InactiveCN104928242AGuaranteed amplification factorGuaranteed cytotoxicityBlood/immune system cellsHuman bodyLymphocyte culture
The invention discloses a culturing method of an NK (natural killer) cell. The culturing method comprises the following steps of (1) separating a mononuclear cell from peripheral blood or umbilical cord blood of a human body; (2) inoculating the mononuclear cell into a culture medium suitable for culturing lymphocyte, adding a CD3 monoclonal antibody, recombinant human interleukin 2 and autologous plasma, and culturing for 3 to 5 days; (3) adding the recombinant human interleukin 2 and the autologous plasma, and culturing; (4) harvesting the NK cell. According to the culturing method of the NK cell, the culturing cost is reduced, the amplification multiple and cell toxicity of the NK cell are guaranteed, the operation time is saved, meanwhile the probability of error operation is reduced, the obtaining efficiency of the NK cell is higher, and the safety of the NK cell is better.
Owner:WUHAN HAMILTON BIOTECH
Method for abundantly amplifying NK (natural killer) cells from mononuclear cell of peripheral blood
ActiveCN107022524AAvoid insecurityHigh purityBlood/immune system cellsPeripheral blood mononuclear cellCD16
The invention relates to a method for abundantly amplifying NK (Natural Killer) cells from a mononuclear cell of peripheral blood. The method comprises the following steps of collecting the mononuclear cell of the peripheral blood, first putting the mononuclear cell into a culture bottle enveloped by a CD16 monoclonal antibody, culturing the mononuclear cell, and adding IL-2, IL-15, OK432 and inactivated autoserum into a culture medium; subsequently, transferring the cell into a culture bottle which is not enveloped by the CD16 monoclonal antibody, culturing the cell, adding the IL-2, the IL-15 and the inactivated autoserum into the culture medium; afterwards, transferring the cell into a culture bag, culturing the cell, and adding IL-4 into the culture medium on the last third day, and continuously culturing the cell, so as to obtain abundant NK cells. According to the method, components of animal serum and a tumor cell are not contained; therefore, the safety and the reliability of the NK cells are improved to a great extent; the method has a favorable application prospect.
Owner:SHANGHAI LIFE SCI & TECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com